Clinical trial

Diabetes Therapy to Improve BMI and Lung Function in CF

NCT00072904

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2001-06-01

PhasePHASE3

Study timeline

Study start (unknown)2001-06-01Date precision: month

Registry last updated2012-02-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Cystic Fibrosisunresolved

Diabetes Mellitusunresolved

Interventions

Insulin AsparteDRUG

RepaglinideDRUG · verified · RxNorm: repaglinide

Sponsors & collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)lead sponsor

Cystic Fibrosis Foundationcollaborator

Novo Nordisk A/Scollaborator

Mapped research locations

TorontoOntario, Canada1 NashvilleTennessee, United States1 PittsburghPennsylvania, United States1 MinneapolisMinnesota, United States1 Salt Lake CityUtah, United States1 Palo AltoCalifornia, United States1 SpringfieldMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00072904 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.